Physician profile
Eva Pilcher
NPI 1033371133
$11,274.59
in general payments reported to CMS, 2019-2025
44 companies · $1,146 in 2025
The $1,146 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,144 · 2020: $533 · 2021: $1,926 · 2022: $2,465 · 2023: $1,792 · 2024: $1,268 · 2025: $1,146.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,197 · Education: $9.43.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,197.42 |
| Education | $9.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $2,013.75 | 2019-2025 | Vumerity, Tysabri, Avonex |
| Amneal Pharmaceuticals LLC | $1,623.62 | 2019-2024 | Rytary, Crexont |
| Abbvie INC. | $1,540.41 | 2021-2025 | |
| Celgene Corporation | $780.02 | 2021-2025 | Zeposia |
| Teva Pharmaceuticals USA, INC. | $709.37 | 2019-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Genzyme Corporation | $413.72 | 2019-2025 | |
| Biohaven Pharmaceuticals, INC. | $399.84 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $379.99 | 2021-2023 | |
| Pfizer INC. | $294.73 | 2023-2025 | |
| Ucb, INC. | $240.98 | 2021-2025 | Rystiggo, Nayzilam, Briviact |
| Novartis Pharmaceuticals Corporation | $213.41 | 2021-2025 | |
| Supernus Pharmaceuticals, INC. | $209.92 | 2019-2022 | |
| Sk Life Science, INC. | $181.98 | 2021-2025 | |
| Genentech USA, INC. | $178.63 | 2022-2025 | Ocrevus, Ocrevus Zunovo, Enspryng |
| Amgen INC. | $167.42 | 2019-2023 | Aimovig |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $166.02 | 2022-2024 | Nuplazid |
| Banner Life Sciences, LLC | $159.75 | 2021-2024 | |
| Lilly USA, LLC | $153.48 | 2019-2023 | Amyvid |
| Allergan, INC. | $143.76 | 2020-2022 | |
| Tg Therapeutics, INC. | $138.79 | 2023-2025 | |
| Acorda Therapeutics, INC | $123.63 | 2019-2023 | Ampyra, Inbrija |
| Sanofi-Aventis U.S. LLC | $109.51 | 2020-2021 | |
| Kyowa Kirin, INC. | $105.39 | 2021-2022 | |
| Livanova USA, INC. | $92.61 | 2021-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Lundbeck LLC | $76.07 | 2024-2025 | Vyepti |
| Alexion Pharmaceuticals, INC. | $76.01 | 2019-2022 | |
| Argenx US, INC. | $75.51 | 2024-2025 | Vyvgart Hytrulo |
| Currax Pharmaceuticals LLC | $74.66 | 2021-2024 | Onzetra Xsail, Contrave |
| Sunovion Pharmaceuticals INC. | $70.24 | 2021-2022 | |
| Emd Serono, INC. | $53.89 | 2019 | |
| Impel Pharmaceuticals INC. | $34.64 | 2023 | Trudhesa |
| Biohaven Pharmaceutical Holding Company Ltd. | $33.45 | 2022 | |
| Corium, LLC | $26.99 | 2023 | Adlarity |
| Otsuka America Pharmaceutical, INC. | $26.17 | 2025 | Rexulti |
| Alnylam Pharmaceuticals INC. | $24.91 | 2021 | |
| Janssen Biotech, INC. | $24.83 | 2025 | |
| Assertio Therapeutics, INC. | $23.45 | 2019 | |
| Akcea Therapeutics, INC. | $20.51 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $18.80 | 2022 | |
| Neurelis, INC. | $16.64 | 2023 | Valtoco |
| Abbott Laboratories | $14.93 | 2024 | Infinity |
| Cycle Pharmaceuticals INC | $14.33 | 2025 | Bafiertam |
| Kedrion Biopharma, INC. | $13.95 | 2024 | Albuked, Rhogam Ultra-Filtered Plus, Kedrab |
| Aprecia Pharmaceuticals, LLC | $13.88 | 2023 | Spritam |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eva Pilcher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.